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This article attempts to define terminology and to describe a process for writing adaptive, early phase study protocols
which are transparent, self-intuitive and uniform. It provides a step by step guide, giving templates from projects which
received regulatory authorisation and were successfully performed in the UK. During adaptive studies evolving data is
used to modify the trial design and conduct within the protocol-defined remit. Adaptations within that remit are
documented using non-substantial protocol amendments which do not require regulatory or ethical review. This
concept is efficient in gathering relevant data in exploratory early phase studies, ethical and time- and cost-effective.
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Background
The use of adaptive study design in early exploratory
clinical drug development, if thoroughly planned, is
beneficial as it allows continuous learning from data
that is being gathered. Thus, the study conduct can be
adjusted accordingly within pre-specified boundaries,
maximising the yield of useful information. Adaptations of
the study conduct are protocol defined design features
and not based on ad-hoc decisions [1]. An adaptive study
protocol needs to be sufficiently detailed, clear and
systematic whilst allowing for flexibility and evolution.
Regulatory acceptability and efficient study conduct
depend on a study protocol that is fit for purpose. It is
desirable to define a uniform and intuitive terminology
for adaptive protocols and to optimize a sufficiently
comprehensive format, allowing the full assessment of
risks and benefits of a proposed protocol, which can be
easily followed in a global environment. The benefit of
a standardised layout is that it facilitates ethical and
regulatory review and makes subsequent adaptive protocol
changes easy to document and follow.* Correspondence: u.lorch@richmondpharmacology.com
1Richmond Pharmacology Ltd, St. George’s University of London, Cranmer
Terrace, London, UK
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unless otherwise stated.In simple terms, there are three major elements to
adaptive protocols in early phase drug development:
1. The description of the changes that can be made to
study design and conduct, i.e. its adaptive features
2. The definition of the boundaries to these changes
beyond which Regulatory and Ethics Committee
approval needs to be obtained prior to implementation
3. The description of control mechanisms setting out
how decisions will be made and how changes to the
study will be managed and by whom
This article attempts to define terminology and to
describe a clear process of writing an adaptive study
protocol for the exploratory development of new medi-
cines. It provides a step by step guide to protocol writing,
including templates from projects we have authorised and
performed in the UK. We have recently published an
example which demonstrates the benefits of this concept
[2]. Exploratory early phase trials are hypothesis forming,
not hypothesis testing. Statistical analysis of these ex-
ploratory trials is descriptive in nature. Our paper does
not aim to deal with statistical aspects of adaptive study
design for confirmatory, hypothesis testing clinical trials.
This manuscript describes a process and not research in
human subjects, material or data, therefore it did not
require REC approval.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lorch et al. BMC Medical Research Methodology 2014, 14:84 Page 2 of 9
http://www.biomedcentral.com/1471-2288/14/84Regulatory background
There are few regulatory guidance documents on the
topic, largely focused on later phase confirmatory studies.
The European Medicines Agency (EMA) published a
Reflection Paper on methodological issues in confirma-
tory clinical trials planned with an adaptive design
(CHMP/EWP/2459/02) in 2007 [3]. The FDA published
a draft Guidance for Industry: Adaptive Design Clinical
Trials for Drugs and Biologics in February 2010 [4]. The
FDA also published a draft Guidance for Industry: Enrich-
ment Strategies for Clinical trials to support approval of
human drugs and biological products in December 2012
which includes adaptive elements [5]. However, these
guidance documents focus on confirmatory, hypothesis
testing studies and do not address the specific issues
surrounding adaptive design in exploratory early phase
studies. There is paucity of publications describing the
practical set-up and conduct of adaptive studies in early
drug development.
Discussion
How to write an adaptive protocol
General process
Adaptive study design can be used in conventional early
phase protocols comprising of just one element, such as
a single ascending dose (SAD) protocol. Whilst the
adaptive design principles can be used in any type of
study, the full potential of adaptive study design can be
exploited in combined or “umbrella” protocols. In an um-
brella protocol a number of conventional studies (such as
SAD, multiple ascending dose (MAD), food effect, drug-
drug interaction, ethnic, age and/or gender comparison
and cardiac safety studies etc.) are contained in one single
study protocol.
The writing of an adaptive protocol commences with
the description of the planned study design prior to any
adaptations. At this stage the protocol looks similar to a
non-adaptive study protocol. It will contain as a mini-
mum a clear plan as to how to perform the dosing and
assessments for the first subject(s) or the first dosing
regimen. Equally, it may contain a plan for the entire
study, including all anticipated dosing regimen and
related assessments. After completing this initial “conven-
tional” stage of protocol writing, the elements required
by adaptive design are added, i.e. its adaptive features,
boundaries and control mechanisms. They enable the
study design to undergo pre-defined and justified evo-
lutions so that for every study participant there is a
valid and reproducible study plan.
How to document adaptive changes to the protocol
All changes to the protocol, resulting from the implemen-
tation of pre-defined adaptive features, need to be fully
documented.Changes within the pre-defined scope, boundaries and
control mechanisms of an adaptive study protocol can
be documented as non-substantial protocol amendments
or in administrative protocol change documents. In the
UK these do not require notification to or authorisation
by the Competent Authority (CA) or the Research Ethics
Committee (REC).
Changes outside the pre-defined scope of an adaptive
protocol, its boundaries or control mechanisms constitute
a substantial protocol amendment and require RA/REC
approval as specified within legislation [6], Figure 1.
Three steps to writing an early phase adaptive study
protocol
Step 1: define and describe adaptive features
Terminology Adaptive features are the characteristics
of pre-defined adaptations that can be made to the
protocol and study conduct.
Description When defining adaptive features one needs
to establish firstly which protocol areas will or may require
flexibility to allow for adaptation, i.e. the categories of
adaptations. Secondly, one needs to establish the details of
potential adaptations, i.e. individual adaptive features. The
use of some adaptive features will be certain from the out-
set (such as dose selection in a study where doses have
not been set in the protocol), others will be optional (such
as inclusion of more or less study participants, data ana-
lysis etc.). The categories and nature of adaptive changes
that may potentially be required due to evolving data are
largely predictable. Therefore, in an early phase protocol
it is advantageous to make a full range of these potential
adaptations available of which all necessary ones can be
implemented without delay.
Step 2: define and describe boundaries
Terminology Boundaries are limits that are agreed by
the CA and describe the perimeter which potential adap-
tations are confined to, focussing on participants’ safety.
Description Boundaries determine adaptive features’
maximum acceptable risk and inconvenience at the one
end of the spectrum and minimum safety requirements
at the other. Boundaries are set for each category and
each of its individual adaptive features. Boundaries are an
essential part of the risk management of a study. Regulatory
acceptability of an adaptive trial depends on the setting of
safe boundaries rather than the permutations and details of
potential adaptations to the study conduct.
Template and examples for step 1 and step 2: adaptive
features and their boundaries Adaptive features and
their boundaries can be systematically pre-defined and
are best described in tabular format which makes all
Figure 1 Amendments for adaptive protocols. *Medicines and Healthcare products Regulatory Agency (MHRA)/National Research Ethics
Service (NRES), UK.
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place. Tables 1, 2, 3, 4 and 5 provide a template with
examples of adaptive features and their boundaries
used in early phase studies authorised and performed
in the UK.
In early phase clinical trials five overarching categor-
ies of adaptive features usually suffice: Investigational Me-
dicinal Product (IMP)/Dose (Table 1), Timing/Scheduling
(Table 2), Study Participants (Table 3), Assessments
(Table 4), Methods and Analysis (Table 5). They are
then broken down in further sub-categories (see Tables 1,
2, 3, 4 and 5; Column 1). Column 2 lists individual
adaptive features within each of these four categories
and their sub-categories. Column 3 lists the boundaries
for each category and its adaptive features, wherever
applicable.
Within the category of assessments (Table 4), due to
lack of human data at the time of protocol writing, it
may not be possible to set fixed boundaries for certain
adaptive features. For instance, the schedule of assess-
ments for First-in-Human studies will be largely based on
pre-clinical data. The actual properties of the IMP in
humans may prove to be different. Permissible assessmentboundaries may therefore be difficult to determine at proto-
col writing stage. If that is so, rather than using arbitrary
boundaries which later prove unsuitable, the protocol can
include more general wording to describe principles and
a process for their application, stipulating that adapta-
tions should be made:
– in accordance with evolving data and dosing
regimen up to the decision making time
point;
– in the spirit of the current study protocol (i.e.
focus on the capture of essential and useful data)
not affecting the authorised risk profile of the
study.
The UK competent authority (MHRA) is open to
proposals for adaptations and will assess these on a
case-by-case basis, taken in the wider context of the
clinical trial.
Step 3: control mechanisms
Terminology Control mechanisms: The mechanisms de-
cision makers use to review data, to make and document
Table 2 Timing/Scheduling
Adaptive study design category Adaptive features Boundaries
Overlap Dosing regimens or discrete parts of umbrella
protocols may overlap
1. Minimum data requirements for progression between
dosing regimens/protocol parts
2. Reference to study specific toxicity rules
Table 1 Investigational medicinal product/dose
Adaptive study design category Adaptive features Boundaries
Dosing regimen 1. Dosing regimens may be determined or
adapted in accordance with pharmacokinetic
(PK), pharmacodynamic (PD), safety and
tolerability data (as applicable) collected up
to the decision making time-point.
1. Maximum starting dose
The term dosing regimen includes (1) the
dose level administered, (2) the frequency of
dosing and (3) the duration of dosing, i.e. the
number of doses administered. Accordingly
these can be adjusted individually or in
combination.
2. Maximum dose or exposure increment
for each dose/exposure escalation step
2. The number of dosing regimens investigated
may be adjusted.
3. Maximum (mean) exposure
4. Minimum/maximum dosing frequency
5. Minimum/maximum treatment duration
6. Permissibility of dosing regimen adaptation
within and/or between cohorts
7. Minimum/maximum number of dosing
regimens to be investigated, safety and
tolerability permitting
8. Dose/exposure relationships between discrete
parts of umbrella protocols (e.g. between SAD
and MAD parts).
Sentinel/sub groups 3. The number and size of sentinel/sub-groups
groups within a dosing regimen may be
adaptable
1. Mandatory sentinel groups for selected dosing
regimens/study parts
2. Maximum sentinel/sub-group group size; maximum
number of study participants receiving IMP at any
one time
3. Minimum time to elapse between sentinel/sub-groups
of a dosing regimen
IMP formulation/mode of administration 4. Adaptable use of different IMP formulations
or modes of administration
1. Formulation/administration characteristics and
requirements
2. Exposure limits (see adaptive feature 1)




Sample size 1. The number of subjects in a dosing regimen/cohort
can be decreased or increased.
1. Minimum data requirements for progression between
dosing regimens/protocol parts
2. Minimum/maximum size of a cohort/dosing regimen
3. IMP/placebo ratio
4. Reference to study specific toxicity rules
Sample size 2. The number of dosing regimens/cohorts may
be decreased or increased
1. Minimum/maximum number of dosing regimens/cohorts
(for each study part of an umbrella study), safety and
tolerability permitting
2. Reference to study specific toxicity rules
Selection criteria 3. Selection criteria may be adaptable 1. Defined criteria for which adaptability is permitted
2. Criteria-specific direction and extent of adaptability
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Table 4 Assessments
Adaptive study design category Adaptive features Boundaries
Assessments 1. Safety/tolerability samples and assessments (such
as safety laboratory, vital signs, electrocardiograms
(ECGs), continuous cardiac monitoring etc.) &
1. Minimum data requirements for progression
between dosing regimens/protocol parts
2. PK/PD/exploratory/other samples and assessments:
2. Defined sampling or assessment types/categories
for which adaptability is permitted
a) Additional or less samples or assessments may be taken 3. Minimum samples/time-points/assessments to
sufficiently cover the full safety/tolerability and PK/PD
profile in relation to relevant doses (e.g. single dose,
steady state)
b) Timing of samples or assessments may be adapted
4. Maximum
-blood (or other) volumes
-number of samples or assessments
-sampling or assessment time-points
Assessments 3. Prolongation or shortening of the in-house period or
out-patient follow-up period
1. Minimum/maximum in-house stay or out-patient
follow-up periods based on:
-study specific safety & tolerability, PK and/or PD
parameters that must be reached prior to discharge
from the clinic/study
-evolving safety and tolerability profile of the IMP
-and evolving PK/PD characteristics of the IMP up to
the decision making time-point
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Progression Rules and Toxicity Rules.
Description During early phase adaptive studies, decision
makers review evolving data at pre-defined decision making
time-points using a defined process. The data is usually
reviewed in a blinded fashion. Following review, decisions
are made on study progression in accordance with the
study’s options, i.e. its design, adaptive features and bound-
aries. The review meetings are minuted, the outcomes are
documented. These documents become part of the Trial
Master File.
Study progression rules The elements of study progres-
sion rules which should be incorporated in an adaptive
study protocol are:




Methods 1. Methodology (such as food, cardiac safety
and other clinical assessments, study specific
techniques) may be adjusted
Analysis 2. Optional analysis of safety, PK/metabolites/PD/
exploratory/other samples/assessments:
a) Analysis may be limited to selected parameters,
dosing regimens and time-points.
b) Timing of optional analysis of certain parameter
may be flexible(2) Decision making process
(a) Review team/decision makers
(b) Blinded/unblinded review
(c) Documentation of decision
(3) Minimum data reviewed at each decision making
time-point
(a) Nature of the data (PK, PD, safety and
tolerability (reviewed in accordance with toxicity
algorithm, see Figure 2)
(b) Number of subjects
(c) Post-dose review time period
(4) Dependencies/next steps following data review at
each decision making time-point
a) Steps to proceed to distinct parts within an
umbrella study
b) Exposure/dose escalation steps within (parts of )
a studyBoundaries
1. Defined methodologies for which adaptability is permitted
2. Permitted purpose of adjustments
3. Decision making time-points when adjustments may be made
1. Minimum data requirements for progression between dosing
regimens/protocol parts
2. Defined sampling or assessment types/categories for which
optional analysis is permitted
s 3. Permitted purpose(s) of optional analyses
4. Reporting (how, where and when) of the optional analyses
Figure 2 Toxicity rules.
Lorch et al. BMC Medical Research Methodology 2014, 14:84 Page 6 of 9
http://www.biomedcentral.com/1471-2288/14/84The detailed content of these protocol elements depend
on the study design, the IMP PK/PD profile and its antici-
pated risks.Template algorithm for step 3: study progression rules
The algorithm (Figure 3) visualises the decision making
time-points, the minimum data reviewed at each deci-
sion making time-point and the next step(s) dependent
on the data reviewed.Toxicity rules Toxicity rules can be efficiently described
using standard terminology and template algorithms,
adapted for each specific study. A suitable system for tox-
icity grading needs to be chosen, taking into consideration
the nature of adverse reactions that may occur. For the
purpose of this manuscript this includes adverse reactions
that are expected in the regulatory sense, i.e. adverse
reactions included in the Reference Safety Information
(RSI) - with information on frequency and nature of the
adverse reaction - for assessing whether a Serious Adverse
Event (SAE) is classified as a Suspected Unexpected Serious
Adverse Reaction (SUSAR).There is usually no RSI during the first year of clinical
development of new medicines, unless the RSI contained
in the Investigator’s Brochure is updated via substantial
amendments in the first year [6-8]. During this time, the
“expectedness” of potential adverse reactions will be
based on pre-clinical data and known class effects. This
does not fall within the regulatory RSI definition but will
nevertheless be clinically relevant for the development of
study specific toxicity rules. Therefore the definition and
basis of the term “expected” and the nature and frequency
of “expected” adverse reactions need to be clearly de-
scribed in the Investigator’s Brochure (e.g. in the Guidance
for Investigators) and referenced in the study protocol.
The “Common Terminology Criteria for Adverse Events
(CTCAE)” [9] provides terminology and toxicity grading
for a wide range of adverse events. It was developed for
oncology trials but can be used with the lower grading in
early phase healthy volunteer and patient studies. The
CTCAE is the most comprehensive reference document
and based on “Medical Dictionary for Regulatory Activities”
(MedDRA) terminology. There are other, more specific
grading systems, such as the FDA’s toxicity grading for
vaccine trials [10]. The chosen grading system should
Figure 3 Study progression rules for an adaptive umbrella study.
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reactions. The CTCAE criteria and their interpretation
are consistent with the standard intensity grading for
Adverse Events during clinical studies: Grade 1 - mild,
Grade 2 - moderate, Grade 3 - severe or medically signifi-
cant, but not immediately life-threatening, may or may
not constitute SAE/SUSAR. Grades 4 and 5 always consti-
tute SAE/SUSAR.
Once a system for toxicity grading has been chosen, a
toxicity rules algorithm is developed for the proposed study
(Figure 2), taking into account toxicity grading, severity/
seriousness, reversibility, “expectedness” and frequency.
Based on these input factors, the algorithm leads to
study specific actions and effects on study progression,
minimising risk.
Template algorithm for step 3: toxicity rules The fre-
quency of Grade 1 toxicities has often little impact on
study progression in early phase studies. Reversibility
within a pre-determined observation period and “expect-
edness” are factors that are usually most relevant in the
consideration of Grade 2 and non-serious Grade 3 toxic-
ities, when decisions on study progression are being made.
There may be compounds for which this is different, in
which case the template algorithm needs adjusting. The
occurrence of one case of a serious Grade 3 toxicity would
normally suspend further dosing at this exposure level
and further dose escalation. Study continuation at a lower
exposure level may be permissible. The occurrence of
Grade 4 or Grade 5 toxicity in a single study participant
would normally suspend a study.
Maintaining the blinding whilst applying the toxicity
algorithm is not problematic, unless higher grade, poten-
tially drug related toxicities occur which may lead tosuspension of the study. In such cases, decision makers
may decide to have the relevant data reviewed unblinded.
If appropriate, this can be done in the first instance by an
independent party, maintaining the investigational staffs’
and decision makers’ blinding.
Practical considerations
Protocol development
A common objection raised in relation to adaptive studies
is the seemingly complex design and protocol development.
The potential introduction of bias undermining the validity
and integrity of the study is another concern commonly
raised. Regulatory acceptability of any type of protocol
depends on a clear description and justification of a
study’s design and its risk management. Study endpoints
and the management of potential risks are the main fac-
tors considered when setting adaptive features, boundaries
and control mechanisms. This is however not specific to
adaptive study design; these factors need to be considered
for any type of protocol, whether adaptive or non-adaptive.
This manuscript shows how the use of a systematic,
standardised 3-step approach can assist the efficient
writing of a complete adaptive protocol. Templates can
be adapted to specific studies and used as checklists to
ensure all potential adaptive features, their boundaries
and study control mechanisms have been considered and
fully described. Provided that such a standard template is
used and operational and technical detail is described in
an operational manual, the writing of an adaptive protocol
is no more complex than the writing of a well-considered,
non-adaptive protocol. In fact, the writing of an adaptive
protocol may be less challenging than the writing of a
non-adaptive protocol; the latter requires accurate predic-
tions of all potential outcomes. Moreover, all predictions
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able completion in accordance with the original study
protocol. Failing that, ad-hoc substantial protocol amend-
ments must be made and approved prior to continuing
a non-adaptive study. Conversely, an adaptive protocol al-
lows well considered and pre-defined adaptations within
their pre-specified boundaries. Adaptive protocols avoid
ad-hoc changes to a study protocol and the resulting po-
tential introduction of bias. An adaptive study can con-
tinue to proceed in accordance with the original protocol.
Implementation of adaptive changes
The flexibility and time savings [11] of an adaptive design
may be lost if interim data at decision making time points
and proposed adaptive changes need to be disseminated
to or authorised by the CA or REC. The UK has a
favourable environment for the conduct of adaptive
studies. The approval of the study protocol is based on
the agreed parameters in terms of acceptable risk and
participant inconvenience, ring-fenced by the adaptive
scope, boundaries and control mechanisms, with a clear
focus on participants’ safety. Once a study protocol has
been approved, there is no further interaction with the
CA/REC so long as the study proceeds within the proto-
col’s pre-defined adaptive specifications. Interactions with
CA/REC are only required if major changes to the proto-
col are proposed, i.e. substantial amendments outside its
adaptive specifications, such as for example increasing the
pre-defined maximum exposure limit, because this could
change the approved balance between risk and benefit.
It is not the role of the CA or REC to routinely check
compliance with the protocol and its approved decision
making processes whilst a study is ongoing. This aspect
is dealt with by distinct Quality Assurance processes such
as audits, inspections and in the UK also the MHRA
Phase 1 Accreditation scheme [12]. Any significant safety
signals will become known to the CA/REC in any case, as
they would either lead to suspension of a study or a sub-
stantial protocol and/or RSI amendment.
Safety
A question raised in relation to adaptive protocol design
is whether it may increase the risk for study participants.
We believe that adaptive studies can be inherently safer
than non-adaptive studies. Adaptive protocols require by
design a continuous assessment of evolving data and well
documented risk management processes. If the protocol is
written as we propose in this manuscript, the maximum
acceptable risk and inconvenience to participants are
clearly confined within a protocol’s adaptive specifications.
Adaptive features remove obstacles to making changes
mandated by new safety data. Finally, adaptive design
avoids collection of unnecessary data and unnecessary ex-
posure to participants.Summary
Adaptive protocol design has universal use across early
phase clinical research. The adaptive concept of using
evolving data to modify the trial design during clinical trial
conduct within the protocol-defined remit is efficient in
gathering meaningful and relevant data, ethical and time-
and cost-effective.
The simple 3-step process of adaptive protocol writing
described in this manuscript may support the wider use
of adaptive protocol design in exploratory early phase
clinical research.
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